Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term adjunctive ganaxolone study in tuberous sclerosis complex-associated epilepsy
MOH_2023-07-12_012812Phase 3Recruiting
- Sponsor
- Marinus Pharmaceuticals
- Start
- Jul 2023
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ganaxolone in epilepsy, sponsored by Marinus Pharmaceuticals. Primary endpoint: Long-term safety. Started Jul 2023; status: recruiting.
02
Drugs
ganaxolone
03
Conditions
epilepsy
Beyond the preview
Go deeper on MOH_2023-07-12_012812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-07-12_012812.